Skip to main content
. Author manuscript; available in PMC: 2017 Nov 7.
Published in final edited form as: Cancer Cell. 2015 Mar 9;27(3):327–341. doi: 10.1016/j.ccell.2015.02.001

Figure 8. Therapeutic options for vismodegib resistant BCC.

Figure 8

(A) Normalized methyl-[3H]-thymidine incorporation of PPT CGNPs transduced with various SMO variants and treated with 500 nM of indicated compounds. Values were normalized to proliferation levels without drug and data plotted are mean +/− SD of triplicates. Note that the residual proliferation of SMO-WT in the presence of drug is due to fibroblast and glial contamination of these primary CGNP cultures.

(B) Same as in (A), but transduced CGNPs were treated with 1 μM of either vismodegib or JQ1.